Wir sind mit live! Mehr erfahren
BIO-Symbol

Bio-Rad Laboratories Class A

353,70 USD
-11,12
3,05 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
353,70
0,00
0 %
1 Tag
-3,05 %
5 Tage
-4,37 %
1 Monat
-6,68 %
3 Monate
17,52 %
6 Monate
21,51 %
Seit Jahresbeginn
15,86 %
1 Jahr
13,22 %
5 Jahre
-51,36 %
10 Jahre
119,16 %
 

Profil: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Mitarbeiter: 7.450

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 33,3 %
Neutral 55,6 %
Negativ 11,1 %
Neutral
Business Wire
vorgestern
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2026 on Wednesday, November 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the.
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
Positiv
MarketBeat
vor 21 Tagen
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
Bio-Rad Laboratories NYSE: BIO is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisitions.
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
Neutral
Seeking Alpha
vor 22 Tagen
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Negativ
Zacks Investment Research
vor 23 Tagen
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
Neutral
Business Wire
letzten Monat
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time. A live webcast and subsequent replay of the event will be available in the Investor Relation.
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
Positiv
Seeking Alpha
letzten Monat
Bio-Rad: Favorable Read-Across From Investor Event
Bio-Rad Laboratories (BIO) remains a Buy, after my assessment of relevant corporate disclosures at the recent Wells Fargo Healthcare conference. Management targets long-term operating margins of 20%, with intermediate milestones in the mid-teens, outpacing consensus expectations. Margin drivers include cost rationalization, AI-driven efficiencies, and a shift toward higher-margin consumables revenue.
Bio-Rad: Favorable Read-Across From Investor Event
Neutral
Seeking Alpha
letzten Monat
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Positiv
Zacks Investment Research
letzten Monat
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
Neutral
Business Wire
letzten Monat
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relati.
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
Positiv
Zacks Investment Research
letzten Monat
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
Kursdiagramme mit Lightweight Charts™ umgesetzt